BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 18192092)

  • 21. Characterization of the human immune response to the UK anthrax vaccine.
    Baillie L; Townend T; Walker N; Eriksson U; Williamson D
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):267-70. PubMed ID: 15364114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased long-term immunity to Bacillus anthracis protective antigen in mice immunized with a CIA06B-adjuvanted anthrax vaccine.
    Wui SR; Han JE; Kim YH; Rhie GE; Lee NG
    Arch Pharm Res; 2013 Apr; 36(4):464-71. PubMed ID: 23440578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Catalytically inactive anthrax toxin(s) are potential prophylactic agents.
    Gupta M; Alam S; Bhatnagar R
    Vaccine; 2007 Dec; 25(50):8410-9. PubMed ID: 17980467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin.
    Gaur R; Gupta PK; Banerjea AC; Singh Y
    Vaccine; 2002 Jun; 20(21-22):2836-9. PubMed ID: 12034111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiation of an anthrax DNA vaccine with electroporation.
    Luxembourg A; Hannaman D; Nolan E; Ellefsen B; Nakamura G; Chau L; Tellez O; Little S; Bernard R
    Vaccine; 2008 Sep; 26(40):5216-22. PubMed ID: 18462850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding of the von Willebrand Factor A Domain of Capillary Morphogenesis Protein 2 to Anthrax Protective Antigen Vaccine Reduces Immunogenicity in Mice.
    de Oliveira FFM; Mamillapalli S; Gonti S; Brey RN; Li H; Schiffer J; Casadevall A; Bann JG
    mSphere; 2020 Jan; 5(1):. PubMed ID: 31941807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice.
    Wui SR; Kim HK; Han JE; Kim JM; Kim YH; Chun JH; Cho YJ; Lee NG
    Int Immunopharmacol; 2011 Sep; 11(9):1195-204. PubMed ID: 21492746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a novel chimeric PA-LF antigen of Bacillus anthracis, its immunological characterization and evaluation as a future vaccine candidate in mouse model.
    Varshney A; Kumar M; Nagar DP; Pal V; Goel AK
    Biologicals; 2019 Sep; 61():38-43. PubMed ID: 31416791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis.
    Rhie GE; Park YM; Han JS; Yu JY; Seong WK; Oh HB
    FEMS Immunol Med Microbiol; 2005 Aug; 45(2):341-7. PubMed ID: 16019195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a novel multiepitope chimeric vaccine against anthrax.
    Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R
    Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice.
    Sloat BR; Cui Z
    J Pharm Pharmacol; 2006 Apr; 58(4):439-47. PubMed ID: 16597361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.
    Kachura MA; Hickle C; Kell SA; Sathe A; Calacsan C; Kiwan R; Hall B; Milley R; Ott G; Coffman RL; Kanzler H; Campbell JD
    J Immunol; 2016 Jan; 196(1):284-97. PubMed ID: 26608924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Production of Functionally Active and Immunogenic Non-Glycosylated Protective Antigen from Bacillus anthracis in Nicotiana benthamiana by Co-Expression with Peptide-N-Glycosidase F (PNGase F) of Flavobacterium meningosepticum.
    Mamedov T; Chichester JA; Jones RM; Ghosh A; Coffin MV; Herschbach K; Prokhnevsky AI; Streatfield SJ; Yusibov V
    PLoS One; 2016; 11(4):e0153956. PubMed ID: 27101370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis.
    Stokes MG; Titball RW; Neeson BN; Galen JE; Walker NJ; Stagg AJ; Jenner DC; Thwaite JE; Nataro JP; Baillie LW; Atkins HS
    Infect Immun; 2007 Apr; 75(4):1827-34. PubMed ID: 17145938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccine.
    Iyer V; Hu L; Schanté CE; Vance D; Chadwick C; Jain NK; Brey RN; Joshi SB; Volkin DB; Andra KK; Bann JG; Mantis NJ; Middaugh CR
    Hum Vaccin Immunother; 2013 Nov; 9(11):2362-70. PubMed ID: 23925275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of three anthrax toxin neutralization assays.
    Ngundi MM; Meade BD; Lin TL; Tang WJ; Burns DL
    Clin Vaccine Immunol; 2010 Jun; 17(6):895-903. PubMed ID: 20375243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax.
    Skoble J; Beaber JW; Gao Y; Lovchik JA; Sower LE; Liu W; Luckett W; Peterson JW; Calendar R; Portnoy DA; Lyons CR; Dubensky TW
    Infect Immun; 2009 Apr; 77(4):1649-63. PubMed ID: 19168734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Presentation of peptides from Bacillus anthracis protective antigen on Tobacco Mosaic Virus as an epitope targeted anthrax vaccine.
    McComb RC; Ho CL; Bradley KA; Grill LK; Martchenko M
    Vaccine; 2015 Nov; 33(48):6745-51. PubMed ID: 26514421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine.
    Chi X; Li J; Liu W; Wang X; Yin K; Liu J; Zai X; Li L; Song X; Zhang J; Zhang X; Yin Y; Fu L; Xu J; Yu C; Chen W
    Clin Vaccine Immunol; 2015 May; 22(5):553-60. PubMed ID: 25787135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.
    Staats HF; Alam SM; Scearce RM; Kirwan SM; Zhang JX; Gwinn WM; Haynes BF
    Infect Immun; 2007 Nov; 75(11):5443-52. PubMed ID: 17709410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.